Search results for "Prostatic neoplasm"

showing 10 items of 285 documents

Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterati…

2011

Considering its long latency, prostate cancer (PCa) represents an ideal target for chemoprevention strategies. Green tea extract (GTE) has been proved to be one of the most promising natural substances capable of inhibiting PCa progression in animal models (transgenic adenocarcinoma of mouse prostate), as well as in humans. However, the cellular targets of the GTE action are mostly unknown. The main objective of this work was to investigate whether the endoplasmic reticulum (ER) and the Golgi apparatus (GA), known to be actively involved in sensing stress stimuli and initiating and propagating cell death signalling, may represent the subcellular targets of GTE action. To this end, 42 TRAMP …

MaleCancer ResearchCellGolgi ApparatusMice TransgenicGreen tea extractAdenocarcinomaEndoplasmic ReticulumCatechinsymbols.namesakeMicegreen tea extract; chemoprevention; prostate cancer; clusterin; ultrastructure; transgenic adenocarcinoma of mouse prostate.medicineAnimalsClusterinbiologyTeaEndoplasmic reticulumProstatic NeoplasmsCell cycleGolgi apparatusCell biologyMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureClusterinOncologyApoptosisgreen tea extract chemoprevention prostate cancer clusterin ultrastructure transgenic adenocarcinoma of mouse prostatesymbolsbiology.proteinProtein Processing Post-TranslationalTrampInternational journal of oncology
researchProduct

Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach.

2009

In this paper, we consider the role of the genetics of inflammation in the pathophysiology of prostate cancer (PCa). This paper is not an extensive review of the literature, rather it is an expert opinion based on data from authors' laboratories on age-related diseases and inflammation. The aim is the detection of a risk profile that potentially allows both the early identification of individuals at risk for disease and the possible discovery of potential targets for medication. In fact, a major goal of clinical research is to improve early detection of age-related diseases, cancer included, by developing tools to move diagnosis backward in disease temporal course, i.e., before the clinical…

MaleCancer ResearchPathologymedicine.medical_specialtyAgingpharmacogenomicmedicine.medical_treatmentImmunologyGenomicsDiseaseBioinformaticsProstate cancerlongevitySettore MED/05 - Patologia ClinicaImmunology and AllergyMedicineHumansGenetic Predisposition to DiseaseSettore MED/04 - Patologia GeneraleInflammationPolymorphism Geneticbusiness.industryCancerProstatic NeoplasmsImmunotherapyprostate cancermedicine.diseaseClinical researchOncologyageingPharmacogeneticsPharmacogenomicsgeneticInflammation MediatorsbusinessPharmacogeneticsCancer immunology, immunotherapy : CII
researchProduct

Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine.

2008

Abstract Purpose: We recently reported that anionic phospholipids, principally phosphatidylserine, become exposed on the external surface of vascular endothelial cells in tumors, probably in response to oxidative stresses present in the tumor microenvironment. In the present study, we tested the hypothesis that a chimeric monoclonal antibody that binds phosphatidylserine could be labeled with radioactive arsenic isotopes and used for molecular imaging of solid tumors in rats. Experimental Design: Bavituximab was labeled with 74As (β+, T1/2 17.8 days) or 77As (β−, T1/2 1.6 days) using a novel procedure. The radionuclides of arsenic were selected because their long half-lives are consistent w…

MaleCancer ResearchPathologymedicine.medical_specialtyBiodistributionBavituximabmedicine.drug_classPhosphatidylserinesMonoclonal antibodyArticleArsenicchemistry.chemical_compoundIn vivomedicineTumor Cells CulturedAnimalsTissue DistributionPlatelet activationRadioisotopesTumor microenvironmentbiologyNeovascularization PathologicAntibodies MonoclonalProstatic NeoplasmsPhosphatidylserineMolecular biologyXenograft Model Antitumor AssaysRatsOncologychemistryRadioimmunodetectionPositron-Emission Tomographybiology.proteinEndothelium VascularAntibodymedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Uncommon Presentations of Non-Hodgkin’s Lymphoma

2003

MaleCancer ResearchPathologymedicine.medical_specialtyLymphoma B-CellProstate biopsyBiopsyDiagnosis DifferentialProstatemedicineHumansProstate diseaseAgedIntravascular large B-cell lymphomaKidneymedicine.diagnostic_testbusiness.industryProstateProstatic Neoplasmsmedicine.diseaseNon-Hodgkin's lymphomamedicine.anatomical_structureOncologyImmunohistochemistrybusinessKidney diseaseJournal of Clinical Oncology
researchProduct

Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.

2013

Intra-tumor injection of immunotherapeutic agents is often the most effective, likely because of concomitant modification of tumor microenvironment. We tested an immunotherapeutic regimen consisting of CpG oligonucleotides and of adenovirus-mediated gene delivery of CCL16 chemokine directly into orthotopically implanted prostate tumors by ultrasound-guided injection, followed by systemic administration of an anti-IL-10R antibody. This combination treatment induced rapid stromal rearrangement, characterized by massive leukocyte infiltration and large areas of necrosis, a scenario that eventually led to complete tumor rejection and systemic immunity in 75 % of the treated mice. In vivo T lymp…

MaleCancer ResearchPathologymedicine.medical_specialtyStromal cellmedicine.medical_treatmentImmunologyFluorescent Antibody TechniqueGene deliveryCD8-Positive T-LymphocytesInjections Intralesionalprostate cancer;immunotherapyAdenoviridaeImmunoenzyme TechniquesProstate cancerMiceTumor Cells CulturedImmunology and AllergyMedicineAnimalsHumansCell ProliferationUltrasonographyTumor microenvironmentbusiness.industryAntibodies MonoclonalProstatic NeoplasmsImmunotherapyT lymphocyteGenetic Therapyprostate cancermedicine.diseaseCombined Modality TherapyInterleukin-10Mice Inbred C57BLOncologyOligodeoxyribonucleotidesChemokines CCSystemic administrationImmunotherapybusinessCD8Cancer immunology, immunotherapy : CII
researchProduct

Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

2013

Several pathologies affect human prostate, such as prostate cancer (PC), which is the most common non-skin malignant cancer in Western male populations. A complex interaction between genetic and environmental factors (i.e. infectious agents, dietary carcinogens) and hormonal imbalances has been reported to have a fundamental role in PC pathophysiology by evoking chronic inflammation. Thus, chronic inflammation drives prostate carcinogenesis and neoplastic progression. No adequate biomarkers exist until now to guide PC prognosis and treatment. Accordingly, the research has particularly focused its attention on genetic variants in genes, codifying molecules of signaling innate immune/inflamma…

MaleCancer ResearchSNPBioinformaticsTranslational Research BiomedicalProstate cancersex steroid and inflammatory networkRisk FactorsmedicineSettore MED/05 - Patologia ClinicaHumansGenetic Predisposition to DiseaseGenetic riskPrecision MedicineGonadal Steroid HormonesMolecular BiologyAllelesSettore MED/04 - Patologia GeneraleInflammationPolymorphism Geneticbusiness.industryrisk profileCancerProstatic NeoplasmsTranslation (biology)prostate cancermedicine.diseasePathophysiologypersonalized PC medicineCell Transformation NeoplasticImmunologygenetic biomarkerDisease ProgressionMolecular MedicinebusinessSignal TransductionCancer gene therapy
researchProduct

Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer.

2021

Abstract Fatal neuroendocrine differentiation (NED) of castration-resistant prostate cancer is a recurrent mechanism of resistance to androgen deprivation therapies (ADT) and antiandrogen receptor pathway inhibitors (ARPI) in patients. The design of effective therapies for neuroendocrine prostate cancer (NEPC) is complicated by limited knowledge of the molecular mechanisms governing NED. The paucity of acquired genomic alterations and the deregulation of epigenetic and transcription factors suggest a potential contribution from the microenvironment. In this context, whether ADT/ARPI induces stromal cells to release NED-promoting molecules and the underlying molecular networks are unestablis…

MaleCancer ResearchStromal cellAnimals Biomarkers Tumor Cell Differentiation Cell Line Tumor Coculture Techniques Endoplasmic Reticulum Chaperone BiP Epigenesis Genetic Gene Expression Regulation Neoplastic Humans Male Mice Mice Inbred C57BL Neuroendocrine Cells Osteonectin Prostatic Neoplasms Stromal Cells Transgenes Tumor Microenvironment Down-RegulationDown-RegulationContext (language use)Settore MED/08 - Anatomia PatologicaNeuroendocrine differentiationEpigenesis GeneticProstate cancerMiceStromaDownregulation and upregulationNeuroendocrine CellsCell Line TumormedicineBiomarkers TumorTumor MicroenvironmentSettore MED/05 - Patologia ClinicaAnimalsHumansOsteonectinEpigeneticsTransgenesEndoplasmic Reticulum Chaperone BiPbusiness.industryMatricellular proteinProstatic NeoplasmsCell Differentiationmedicine.diseaseCoculture TechniquesGene Expression Regulation NeoplasticMice Inbred C57BLOncologyCancer researchStromal CellsbusinessCancer research
researchProduct

Optimal local control and tolerability of three-dimensional conformal radiation therapy in prostate cancer: A single institutional experience of dose…

2013

Aims To evaluate long-term late side effects, clinical and biochemical relapse in non-metastatic prostate cancer patients treated with dose escalation, from 74 to 78 Gy, by means of three dimensional conformal radiation therapy. Materials and Methods Clinical data of 125 patients with prostate cancer who underwent three-dimensional conformal radiation therapy were retrospectively evaluated. All patients were stratified, according to the NCCN classification, in low, intermediate and high risk, and all of them showed histologically proven adenocarcinoma stage T1–T3 with at least 2 years of follow-up. Late toxicity was analyzed using a modified Radiation Therapy Oncology Group toxicity scale. …

MaleCancer ResearchThree dimensional conformal radiation therapyUrinary BladderUrogenital SystemKaplan-Meier EstimateAdenocarcinomaDisease-Free SurvivalBiomarkers Tumor80 and overHumansLate toxicity; Local control; Prostate cancer; Radiation therapy; Three dimensional conformal radiation therapy; Adenocarcinoma; Aged; Aged 80 and over; Biomarkers Tumor; Disease-Free Survival; Gastrointestinal Tract; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Conformal; Rectum; Retrospective Studies; Urinary Bladder; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiation InjuriesAgedNeoplasm StagingRetrospective StudiesAged 80 and overProstate cancerTumorRadiotherapyConformalMedicine (all)RectumProstatic NeoplasmsRadiotherapy DosageGeneral MedicineMiddle AgedProstate-Specific AntigenRadiation therapyGastrointestinal TractItalyOncologyLocal controlRadiotherapy ConformalLate toxicityBiomarkers
researchProduct

Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of th…

2021

Abstract Background Current knowledge about the promotion of long-term physical activity (PA) maintenance in cancer survivors is limited. The aims of this study were to 1) determine the effect of self-regulatory BCTs on long-term PA maintenance, and 2) identify predictors of long-term PA maintenance in cancer survivors 12 months after participating in a six-month exercise intervention during cancer treatment. Methods In a multicentre study with a 2 × 2 factorial design, the Phys-Can RCT, 577 participants with curable breast, colorectal or prostate cancer and starting their cancer treatment, were randomized to high intensity exercise with or without self-regulatory behaviour change technique…

MaleCancer ResearchTime FactorsCancer survivorsLogistic regressionBody Mass Indexlaw.inventionTobacco UseProstate cancerRandomized controlled trialBehavior TherapylawOdds RatioMedicineRC254-282DeterminantsHigh intensityNeoplasms. Tumors. Oncology. Including cancer and carcinogensBehaviour changeMiddle AgedBehavioural supportEndurance TrainingVDP::Medisinske Fag: 700::Helsefag: 800OncologySelf-regulationRegression AnalysisFemaleColorectal NeoplasmsMonth follow upmedicine.medical_specialtyBehaviour changeMaintenancePhysical activityBreast NeoplasmsSelf-ControlConfidence IntervalsGeneticsHumansExerciseSwedenMotivationCancer och onkologibusiness.industryResearchProstatic NeoplasmsCancerResistance Trainingmedicine.diseaseActigraphyCancer and OncologyQuality of LifePhysical therapybusinessFollow-Up StudiesBMC Cancer
researchProduct

Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells

2013

International audience; The proapoptotic protein, prostate apoptosis response-4 (Par-4), acts as a tumor suppressor in prostate cancer cells. The serine/threonine kinase casein kinase 2 (CK2) has a well-reported role in prostate cancer resistance to apoptotic agents or anticancer drugs. However, the mechanistic understanding on how CK2 supports survival is far from complete. In this work, we demonstrate both in rat and humans that (i) Par-4 is a new substrate of the survival kinase CK2 and (ii) phosphorylation by CK2 impairs Par-4 proapoptotic functions. We also unravel different levels of CK2-dependent regulation of Par-4 between species. In rats, the phosphorylation by CK2 at the major si…

MaleCancer Researchanimal structuresCK2[SDV]Life Sciences [q-bio]ImmunologyAmino Acid MotifsPAWR[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC]Biology[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biology[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyCellular and Molecular NeuroscienceProstate cancer[SDV.CAN] Life Sciences [q-bio]/CancerProstateCell Line Tumor[SDV.BC.BC] Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC]medicineAnimalsHumansCasein Kinase IIComputingMilieux_MISCELLANEOUSGene knockdownKinasephosphorylationfungita1182apoptosisProstatic Neoplasms[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyCell Biologymedicine.diseaseprostate cancer[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyRatsmedicine.anatomical_structureApoptosisembryonic structuresCancer researchPhosphorylationOriginal ArticleCasein kinase 2Apoptosis Regulatory ProteinsPar-4
researchProduct